Dr. Zheng co-founded OncoImmune and served as its Chief Medical Officer until its successful exit.  Dr. Zheng led OncoImmune’s clinical development including first-in-human trials in healthy volunteers and cancer patients, as well as successful completion of a Phase II and a Phase III clinical trial establishing the safety and therapeutic efficacy of OncoImmune’s flagship products. Prior to serving as OncoC4’s CMO, Dr. Zheng was on faculty in academic institutions, including the Ohio State University, the Children’s National Medical Center and Institute of Human Virology at University of Maryland School of Medicine. Dr. Zheng was trained in anatomic and clinical pathology and is a board-certified Physician with the American Board of Pathology.